Antitumor effects of bisphosphonates: From the laboratory to the clinic

Current Opinion in Supportive and Palliative Care

Volumn 5, Issue 3, 2011, Pages 233-240

  Berenson, James R ^a  

^a INSTITUTE FOR MYELOMA AND BONE CANCER RESEARCH   (United States)

Author keywords

Angiogenesis; Antitumor effects; Bisphosphonates; Immunostimulatory

Indexed keywords

ANTINEOPLASTIC AGENT; BISPHOSPHONIC ACID DERIVATIVE; BONE DENSITY CONSERVATION AGENT; CELL ADHESION MOLECULE; IMIDAZOLE DERIVATIVE; PAMIDRONIC ACID; ZOLEDRONIC ACID;

APOPTOSIS; BREAST TUMOR; FEMALE; HUMAN; MALE; MULTIPLE MYELOMA; PROSTATE TUMOR; REVIEW;

ANTINEOPLASTIC AGENTS; APOPTOSIS; BONE DENSITY CONSERVATION AGENTS; BREAST NEOPLASMS; CELL ADHESION MOLECULES; DIPHOSPHONATES; FEMALE; HUMANS; IMIDAZOLES; MALE; MULTIPLE MYELOMA; PROSTATIC NEOPLASMS;

EID: 80052707747     PISSN: 17514258     EISSN: 17514266     Source Type: Journal    
DOI: 10.1097/SPC.0b013e328349dc17     Document Type: Review

References (110)

1. Berenson J, Lichtenstein A, Porter L, et al. Efficacy of pamidronate in reducing skeletal events in patients with advanced multiple myeloma: Myeloma Aredia Study Group. N Engl J Med 1996; 334:488-493. (Pubitemid 26067736)
2. Lipton A, Theriault RL, Hortobagyi G, et al. Pamidronate prevents skeletal complications and is effective palliative treatment in women with breast carcinoma and osteolytic bone metastases: long-term follow-up from two randomized, placebo-controlled trials. Cancer 2000; 88:1082-1090. (Pubitemid 30127670)
3. Rosen LS, Gordon D, Kaminski M, et al. Zoledronic acid versus pamidronate in the treatment of skeletal metastases in patients with breast cancer or osteolytic lesions of multiple myeloma: a phase III, double-blind, comparative trial. Cancer J 2001; 7:377-387. (Pubitemid 33759002)
4. Kohno N, Aogi K, Minami H, et al. Zoledronic acid significantly reduces skeletal complications compared with placebo in Japanese women with bone metastases from breast cancer: a randomized, placebo-controlled trial. J Clin Oncol 2005; 23:3314-3321.
5. Saad F, Gleason Murray R, et al. Long-term efficacy of zoledronic acid in for the prevention of skeletal complications in patients with metastatic hormonerefractory prostate cancer. J Natl Cancer Inst 2004; 96:879-882. (Pubitemid 38807610)
6. Rosen LS, Gordon D, Tchekmedyian NS, et al. Long-term efficacy and safety of zoledronic acid in the treatment of skeletal metastases in patients with nonsmall lung carcinoma and other solid tumors: a randomized, phase III, double-blind, placebo-controlled trial. Cancer 2004; 100:2613-2621. (Pubitemid 38715767)
7. Aparicio A, Gardner A, Tu Y, et al. In vitro cytoreductive effects on multiple myeloma cells induced by bisphosphonates. Leukemia 1998; 12:220-229. (Pubitemid 28108075)
8. Fromigue O, Lagneaux L, Body JJ. Bisphosphonates induce breast cancer death in vitro. J Bone Miner Res 2000; 15:2211-2221.
9. Senaratne SG, Pirianov G, Mansi JL, et al. Bisphosphonates induce apoptosis in human breast cancer cell lines. Br J Cancer 2000; 82:1459-1468. (Pubitemid 30175914)
10. Oades GM, Senaratne SG, Clarke IA, et al. Nitrogen containing bisphosphonates induce apoptosis and inhibit the mevalonate pathway, impairing Ras membrane localization in prostate cancer cells. J Urol 2003; 170:246-255.
11. Yaccoby S, Pearse RN, Johnson CL, et al. Myeloma interacts with the bone marrow microenvironment to induce osteoclastogenesis and is dependent on osteoclast activity. Br J Haematol 2002; 116:278-290. (Pubitemid 34156975)
12. Croucher PI, De Raeve H, Perry MJ, et al. Zoledronic acid treatment of 5T2MM-bearing mice inhibits the development of myeloma bone disease: evidence for decreased osteolysis, tumor burden and angiogenesis, and increased survival. J Bone Miner Res 2003; 18:482-492. (Pubitemid 36241065)
13. Hiraga T, Williams PJ, Ueda A, et al. Zoledronic acid inhibits visceral metastases in the 4T1/luc mouse breast cancer model. Clin Cancer Res 2004; 10:4559-4567. (Pubitemid 38878900)
14. Hiraga T, Williams PJ, Mundy GR, et al. The bisphosphonate ibandronate promotes apoptosis in MDA-MD-231 human breast cancer cells in bone metastases. Cancer Res 2001; 61:4418-4424. (Pubitemid 32685769)
15. Yamagishi S-I, Abe R, Inagaki Y, et al. Minodronate, a newly developed nitrogen-containing bisphosphonate, suppresses melanoma growth and improves survival in nude mice by blocking vascular endothelial cell signaling. Am J Pathol 2004; 165:1865-1874. (Pubitemid 39578366)
16. Yang M, Burton DW, Geller J, et al. The bisphosphonate olpadronate inhibits skeletal prostate cancer progression in a green fluorescent protein nude mouse model. Clin Cancer Res 2006; 12:2602-2606.
17. Wakchoure S, Merrell MA, Aldrich W, et al. Bisphosphonates inhibit the growth of mesothelioma cells in vitro and in vivo. Clin Cancer Res 2006; 12:2862-2868.
18. Ory B, Heymann M-F, Kamijo A, et al. Zoledronic acid suppresses lung metastases and prolongs overall survival of osteosarcoma-bearing mice. Cancer 2005; 104:2522-2529. (Pubitemid 41691577)
19. Martin CK, Werbeck JL, Thudi NK, et al. Zoledronic acid reduces bone loss and tumor growth in an orthotopic model of osteolytic oral squamous cell carcinoma. Cancer Res 2010; 8607-8611.
20. Zhou Z, Guan H, Duan X, et al. Zoledronic acid inhibits primary bone tumor growth in Ewing sarcoma. Cancer 2005; 104:1713-1720. (Pubitemid 41437436)
21. Thudi NK, Martin CK, Nadella MV, et al. Zoledronic acid decreased osteolysis but not bone metastases in a nude mouse model of canine prostate cancer with mixed bone lesions. Prostate 2008; 68:1116-1125. (Pubitemid 351875183)
22. Dallas SL, Garrett IR, Oyajobi BO, et al. Ibandronate reduces osteolytic lesions but not tumor burden in a murine model of myeloma bone disease. Blood 1999; 93:1697-1706. (Pubitemid 29102498)
23. Kostenuik PJ, Orr FW, Suyama K, Singh G. Increased growth rate and tumor burden of spontaneously metastatic Walker 256 cancer cells in the skeleton of bisphosphonate-treated rats. Cancer Res 1993; 53:5452- 5457. (Pubitemid 23342166)
24. Daubine F, Le Gall C, Gasser J, et al. Antitumor effects of clinical dosing regimens of bisphosphonates in experimental breast cancer bone metastasis. J Natl Cancer Instit 2007; 99:322-330. (Pubitemid 47073494)
25. Odri GA, Dumoucel S, Picarda G, et al. Zoledronic acid: a new adjuvant therapeutic strategy for Ewing's sarcoma patients. Cancer Res 2010; 70:7610-7619.
26. Hirbe AC, Roelofs AJ, Floyd DH, et al. The bisphosphonate zoledronic acid decreases tumor growth in bone in mice with defective osteoclasts. Bone 2009; 44:908-916.
27. Murayama T, Kawasoe Y, Yamashita Y, et al. Efficacy of the third-generation bisphosphonate risedronate alone and in combination with anticancer drugs against osteosarcoma cell lines. Anticancer Res 2008; 28:2147-2154.
28. Clyburn RD, Reid P, Evans CA, et al. Increased antitumour effects of doxorubicin and zoledronic acid in prostate cancer cells in vitro: supporting the benefits of combination therapy. Cancer Chemother Pharmacol 2010; (6515):969-978.
29. Inoue K, Kayrashima T, Fukata S, et al. Effect of combination therapy with a novel bisphosphonate. minodronate (YM529), and docetaxel on a model of bone metastasis by human transitional cell carcinoma. Clin Caner Res 2005; 11:6669-6677. (Pubitemid 41339008)
30. Ottewell PD, Deux B, Monkkonen H, et al. Differential effect of doxorubicin and zoledronic acid on intraosseous versus extraosseous breast cancer growth in vivo. Clin Cancer Res 2008; 14:4658-4666.
31. van Beek ER, Lowik CWGM, van Wijngaarden J, et al. Synergistic effect of bisphosphonate and docetaxel on the growth of bone metastasis in an animal model of established metastatic bone disease. Breast Cancer Res Treat 2009; 118:307-313.
32. Brubaker KD, Brown LG, Vessella Rl, et al. Administration of zoledronic acid enhances the effects of docetaxel on growth of prostate cancer cells in the bone microenvironment. BMC Cancer 2006; 6:15.
33. Yano S, Zhang H, Hanibuchi M, et al. Combined therapy with a new bisphosphonate, minodronate (YM529), and chemotherapy for multiple organ metastases of small cell ling cancer cells in severe combined immunodeficient mice. Clin Cancer Res 2003; 9:5380-5385. (Pubitemid 37413593)
34. Tassone P, Forciniti S, Galea E, et al. Growth inhibition and synergistic induction of apoptosis by zoledronate and dexamethasone in human myeloma cell lines. Leukemia 2000; 14:841-844. (Pubitemid 30235061)
35. Ural AU, Yilmaz MI, Avcu F, et al. The bisphosphonate zoledronic acid induces cytotoxicity in human myeloma cell lines with enhancing effects of dexamethasone and thalidomide. Int J Hematol 2003; 78:443-449. (Pubitemid 37549625)
36. Abeltino M, Bonomini S, Bolzoni M, et al. The proapoptotic effect of zoledronic acid is independent of either the bone microenvironment or the intrinsic resistance to bortezomib of myeloma cells and is enhanced by the combination with arsenic trioxide. Exp Hematol 2011; 39:55-65.
37. Neville-Webbe HL, Coleman RE, Holen I. Combined effects of the bisphosphonate, zoledronic acid and the aromatase inhibitor letrozole in breast cancer cells in vitro; evidence of synergistic interaction. Br J Cancer 2010; 102:1010-1017. Study shows the enhancing effects of ZOL on the antitumor effects of aromatase inhibitors in breast cancer.
38. + leukemia activity of imatinib mesylate. Blood 2003; 102:2229-2235. (Pubitemid 37122403)
39. Chuah C, Barnes DJ, Kwok M, et al. Zoledronate inhibits proliferation and induces apoptosis of imatinib-resistant chronic myeloid leukemia cells. Leukemia 2005; 19:1896-1904. (Pubitemid 41553997)
40. Kim S-J, Uehara H, Yazici S, et al. Modulation of bone microenvironment with zoledronate enhances the therapeutic effects of STI571 and paclitaxel against experimental bone metastasis of human prostate cancer. Cancer Res 2005; 65:3707-3715. (Pubitemid 40616348)
41. Sonneman J, Bumbul B, Beck JF. Synergistic activity of the histone deacetylase inhibitor suberoylanilide hydroxamic acid and the bisphosphonates zoledronic acid against cancer cells in vitro. Mol Cancer Ther 2007; 6:2976-2984. (Pubitemid 350206776)
42. Moriceau G, Ory B, Mitrofan L, et al. Zoledronic acid potentiates mTOR inhibition and abolishes the resistance of osteosarcoma cells to RAD001 (everolimus): pivotal role of the prenylation process. Cancer Res 2010; 70:10239-110239.
43. Zhang W, Zhu X-D, Sun H-C, et al. Depletion of tumor-associated macrophages enhances the effect of sorafenib in metastatic liver cancer models by antimetastatic and antiangiogenic effects. Clin Cancer Res 2010; 16:3420- 3430.
44. Luckman SP, Coxon FP, Ebeting FH, et al. Heterocycle-containing bisphosphonates cause apoptosis and inhibit bone resorption by preventing protein prenylation: evidence from structure-activity relationships in J774 macrophages. J Bone Miner Res 1998; 13:1668-1678. (Pubitemid 28491995)
45. Corsini A, Bellosta S, Baetta R, et al. New insights into the pharmacokinetic and pharmacodynamic properties of statins. Pharmacol Ther 1999; 84:413- 428.
46. Rogers MJ. From molds and macrophages to mevalonate: a decade of progress in understanding the molecular mode of action of bisphosphonates. Calcif Tissue Int 2004; 75:451-461. (Pubitemid 40174502)
47. Otsuki T, Sagaguchi H, Hatayama T, et al. Effects of an HMG-CoA reductase, simvastatin, on human myeloma cells. Oncol Rep 2004; 11:105301058.
48. van de Donk NW, Kaphuis MM, Lokhorst HM, et al. The cholesterol lower drug lovastatin induces cell death in myeloma plasma cells. Leukemia 2002; 16:1362-1371.
49. Schmidmaier R, Simsek M, Baumann P, et al. Synergistic antimyeloma effects of zoledronate and simvastatin. Anti-Cancer Drugs 2006; 17:621-629. (Pubitemid 44265862)
50. Pan J, Yeung S-CJ. Recent advances in understanding the antineoplastic mechanisms of farnesyl transferase inhibitors. Cancer Res 2005; 65:9109- 9112. (Pubitemid 41507967)
51. Efuet ET, Keyomarsi K. Farnesyl and geranylgeranyl transferase inhibitors induceG1 arrest by targeting the proteasome. Cancer Res 2006; 66:1040- 1051. (Pubitemid 43165972)
52. Hasmim M, Bieler G, Ruegg C. Zoledronate inhibits endothelial cell adhesion, migration and survival through the suppression of multiple, prenylation-dependent signaling pathways. J Thromb Haemost 2007; 5:166-173. (Pubitemid 44921082)
53. Tassone P, Tagliaferri P, Viscomi C, et al. Zoledronic acid induces antiproliferative and apoptotic effects in human pancreatic cancer cells in vitro. Br J Cancer 2003; 88:1971-1978. (Pubitemid 36829676)
54. Sewing L, Steinberg F, Schmidt H, et al. The bisphosphonate zoledronic acid inhibits the growth of HCT-116 colon carcinoma cells and induces tumor cell apoptosis. Apoptosis 2008; 13:782-789.
55. Almubarak H, Jones A, Chaisuparat R, et al. Zoledronic acid directly suppresses cell proliferation and induces apoptosis in highly tumorigenic prostate and breast cancers. J Carcinog 2011; 10:2.
56. Ory B, Blanchard F, Battaglia S, et al. Zoledronic acid activates the DNA Sphase checkpoint and induces osteosarcoma cell death characterized by apoptosis-inducing factor and endonuclease-G translocation independently of p53 and retinoblastoma status. Mol Pharmacol 2007; 71:333- 343. (Pubitemid 46021003)
57. Tanimori Y, Tsubaki M, Yamazoe Y, et al. Nitrogen-containing bisphosphonate, YM529/ONO-5920, inhibits tumor metastasis in mouse melanoma through suppression of the Rho/ROCK pathway. Clin Exp Metastasis 2010; 27:529-538.
58. Mitrofan LM, Castells FB, Pelkonen J, et al. Lysosomal-mitochondrial axis in zoledronic acid-induced apoptosis in follicular lymphoma cells. J Biol Chem 2010; 285:1967-1979. Provides an alternative explanation for the antitumor effects of N-BPs.
59. Ziebart T, Past A, Klein Mo, et al. Bisphosphonates: restrictions for vasculogenesis and angiogenesis: inhibition of cell function of endothelial progenitor cells and mature endothelial cells in vitro. Clin Oral Investig 2011; 15:105-111. This study provides evidence for inhibitory effects of bisphosphonates on multiple cell types involved in blood vessel formation.
60. Fournier P, Boissier S, Filleur S, et al. Bisphosphonates inhibit angiogenesis in vitro and testosterone-stimulated vascular regrowth in the ventral prostate in castrated rats. Cancer Res 2002; 62:6538-6544. (Pubitemid 35364119)
61. Chen H, Wang CS, Li M, et al. A novel angiogenesis model for screening antiangiogenic compounds: the chorioallantoic membrane/feather bud assay. Int J Oncol 2010; 37:71-79.
62. Giraudo E, Inoue M, Hanahan D. An amino-bisphosphonate targets MMP-9- expressing macrophages and angiogenesis to impair cervical carcinogenesis. J Clin Invest 2004; 114:623.
63. Moschetta M, Di Pietro G, Ria R, et al. Bortezomib and zoledronic acid on angiogenic and vasculogenic activities of bone marrow macrophages in patient with multiple myeloma. Eur J Cancer 2010; 46:420-429.
64. Santini D, Vincenzi G, Avvisati G, et al. Pamidronate induces modifications of circulating angiogenic factors in cancer patients. Clin Cancer Res 2002; 8:1080-1084. (Pubitemid 34517643)
65. Santini D, Vincenzi G, Dicuonzo G, et al. Zoledronic acid induces significant and long-lasting modifications of circulating angiogenic factors in cancer patients. Clin Cancer Res 2003; 9:2893-2897. (Pubitemid 36993246)
66. Van der Pluijm G, Vloedgraven HJ, van Beek E, et al. Bisphosphonates inhibit the adhesion of breast cancer cells to bone matrices in vitro. J Clin Invest 1996; 98:698-705. (Pubitemid 26349174)
67. Boissier S, Magnetto S, Frappart L, et al. Bisphosphonates inhibit prostate and breast carcinoma cell adhesion to unmineralized and mineralized bone extracellular matrices. Cancer Res 1997; 57:3890-3894. (Pubitemid 27427670)
68. Corso A, Ferretti E, Lunghi M, et al. Zoledronic acid down-regulates adhesion molecules of bone marrow stromal cells in multiple myeloma: a possible mechanism for its antitumor effect. Cancer 2005; 104:118-125. (Pubitemid 40847759)
69. Virtanen SS, Vaananen HK, Harkonen PL, et al. Alendronate inhibits invasion of PC-3 prostate cancer cells by affecting the mevalonate pathway. Cancer Res 2002; 62:2708-2714. (Pubitemid 34462756)
70. Sawada K, Morishige K-I, Tahara M, et al. Alendronate inhibits lysophatidic acid-induced migration of human ovarian cancer cells by attenuating the activation of Rho. Cancer Res 2002; 62:6015-6020. (Pubitemid 35244445)
71. Boissier S, Ferraras M, Peyruchaud O, et al. Bisphosphonates inhibit breast and prostate carcinoma cell invasion, an early event in the formation of bone metastases. Cancer Res 2000; 60:2949-2954. (Pubitemid 30395820)
72. Denoyelle C, Hong L, Vannier J-P, et al. New insights into the actions of bisphosphonates zoledronic acid in breast cancer cells by dual RhoAdependent and -independent effects. Br J Cancer 2003; 88:1631-1640. (Pubitemid 36713793)
73. Miwa S, Mizokami A, Keller ET, et al. The bisphosphonate YM529 inhibits osteolytic and osteoblastic changes and CXCR-4-induced invasion in prostate cancer. Cancer Res 2005; 65:8818-8825. (Pubitemid 41377370)
74. Derenne S, Amiot M, Barille S, et al. zoledronate is a potent inhibitor of myeloma cell growth and secretion of IL-6 and MMP-1 by the tumoral environment. J Bone Miner Res 1999; 14:2028-2056.
75. Stearns ME, Wang M. Alendronate blocks metalloproteinase secretion and bone collagen I release by PC-3 ML cells in SCID mice. Clin Exp Metastasis 1998; 16:693-702. (Pubitemid 29170479)
76. Melani C, Sangaletti S, Barazetta FM, et al. Amino-bisphosphonate- mediated MMP-9 inhibition breaks the tumor-bone marrow axis responsible for myeloid- derived suppressor cell expansion and macrophage infiltration in tumor stroma. Cancer Res 2007; 67:11438-11446. (Pubitemid 350248572)
77. MMP-9 inhibition breaks the tumor-bone marrow axis responsible for myeloid- derived suppressor cell expansion and macrophage infiltration in tumor stroma. Cancer Res 2007; 67:11438-11446. (Pubitemid 350248572)
78. Han JH, Choi SJ, Kurihara N, et al. Macrophage inflammatory protein 1alpha is an osteoclastogenic factor in myeloma that is independent of receptor activator of nuclear factor kappaB ligand. Blood 2001; 97:3349- 3353.
79. Lentzsch S, Gries M, Janz M, et al. Macrophage inflammatory protein 1-alpha (MIP-1 alpha) triggers migration and signaling cascades mediating survival and proliferation in multiple myeloma (MM) cells. Blood 2003; 101:3568- 3573. (Pubitemid 36857943)
80. Espinoza I, Liu H, Busby R, et al. CCN1, a candidate target for zoledronic acid treatment in breast cancer. Mol Cancer Ther 2011; 10:732-741.
81. Kunzmann V, Bauer E, Feurle J, et al. Stimulation of gammadelta T cells by aminobisphosphonates and induction of antiplasma cell activity in multiple myeloma. Blood 2000; 96:384-392. (Pubitemid 30463353)
82. Bukowski JF, Dascher CC, Das H. Alternative bisphosphonate targets and mechanisms of action. Biochem Biophys Res Comm 2005; 328:746-750. (Pubitemid 40208312)
83. Abe Y, Muto M, Nieda M, et al. Clinical and immunological evaluation of zoledronate-activated Vgamma9gammadelta T-cell-based immunotherapy for patients with multiple myeloma. Exp Hematol 2009; 37:956-968.
84. Uchida R, Asihara E, Sato K, et al. Gamma delta T cells kill myeloma cells by sensing mevalonic acid metabolites and ICAM-1 molecules on cell surface. Biochem Biophys Res Comm 2007; 354:613-618. (Pubitemid 46161370)
85. Meriviglia S, Eberl M, Vermijlen D, et al. In vivo manipulation of Vgamma9delta2 T cells with zoledronate and interleukin 2 for immunotherapy of advanced breast cancer patients. Clin Exp Immunol 2010; 161:290- 297.
86. Dieli F, Vermijlen D, Fulfaro F, et al. Targeting human gd T cells with zoledronate and interleukin-2 for immunotherapy of hormone-refractory prostate cancer. Cancer Res 2007; 67:7450-7457. (Pubitemid 47206575)
87. Waterman GN, Yellin O, Jamshidinia K, et al. Metatarsal stress fractures in six multiple myeloma patients with long-term bisphosphonates. J Bone Joint Surg (in press).
88. Dhodapkar MV, Singh J, Mehta J, et al. Antimyeloma activity of pamidronate in vivo. Br J Haematol 1998; 103:530-532.
89. McCloskey EV, MacLennan ICM, Drayson MT, et al. A randomized trial of the effect of clodronate on skeletal morbidity in multiple myeloma. Br J Haematol 1998; 100:317-325. (Pubitemid 28131063)
90. Berenson JR, Lichtenstein A, Porter L, et al. Long-term pamidronate treatment of advanced multiple myeloma patients reduces skeletal events. J Clin Oncol 1998; 16:593-602. (Pubitemid 28135605)
91. Berenson J, Dimopoulos M, Chen Y-M. Improved survival in patients with multiple myeloma and high BALP levels treated with zoledronic acid compared with pamidronate: univariate and multivariate models of hazard ratios. Presented at 48th ASH Annual Meeting and Exposition; 9-12 December 2006; Orlando, FL (Abstract 3589).
92. Aviles A, Nambo MJ, Neri N, et al. Antitumor activity of zoledronic acid in previously untreated patients with multiple myeloma. Med Oncol 2007; 24:227-230. (Pubitemid 350135975)
93. Musto P, Petrucci MT, Bringhen S, et al. A multicenter, randomized clinical trial comparing zoledronic acid versus observation in patients with asymptomatic myeloma. Cancer 2008; 113:1588-1595.
94. D'Arena G, Gobbi PG, Broglia C, et al. Pamidronate versus observation in asymptomatic myeloma: final results with long-term follow-up of a randomized study. Leuk Lymphoma 2011; 52:771-775.
95. Morgan G, Davies FE, Gregory WM, et al. Fist-line treatment with zoledronic acid as compared with clodronic acid in multiple myeloma (MRC Myeloma IX): a randomized controlled trial. Lancet 2010; 376:1989-1999. Randomized clinical trial demonstrating an overall survival advantage with monthly ZOL compared to daily oral CLO in previously untreated multiple myeloma patients also receiving anti-multiple myeloma therapy.
96. Henry DH, Costa L, Goldwasser F, et al. Randomized, double-blind study of denosumab versus zoledronic acid in the treatment of bone metastases in patients with advanced cancer (excluding breast and prostate cancer) or multiple myeloma. J Clin Oncol 2011; 29:1125-1132.
97. Body JJ, Facon T, Coleman RE, et al. A study of the biological receptor activator of nuclear factor-kappaB ligand inhibitor, denosumab, in patients with multiple myeloma or bone metastases from breast cancer. Clin Cancer Res 2006; 12:1221-1228. (Pubitemid 43342512)
98. Pennisi A, Li X, Ling W, et al. The proteasome inhibitor bortezomib suppresses primary myeloma and stimulates bone formation in myelomatous and nonmyelomatous bones in vivo. Am J Hematol 2009; 84:6-14.
99. Zangari M, Pappas L, Zhan F, et al. Parathyroid hormone (PTH) serum variations are associated with bortezomib response in multiple myeloma patients. Blood 2008; 112:2783.
100. Deleu S, Lemaire M, Arts J, et al. Bortezomib alone or in combination with the histone deacetylase inhibitor JNJ-26481585: effect on myeloma disease in the 5T2MM murine model of myeloma. Cancer Res 2009; 69:5307-5311.
101. Giuliani N, Morandi F, Tagliaferri S, et al. The proteasome inhibitor bortezomib affects osteoblast differentiation in vitro and in vivo in multiple myeloma patients. Blood 2007; 110:334-338. (Pubitemid 47026851)
102. Ozaki S, Tanaka O, Fujii S, et al. Therapy with bortezomib plus dexamethasone induces osteoblast activation in responsive patients with multiple myeloma. Int J Hematol 2007; 86:180-185. (Pubitemid 47425199)
103. Anderson G, Gries M, Kurihara N, et al. Thalidomide derivative CC-4047 inhibits osteoclast formation by downregulation of PU.1. Blood 2006; 107:3098-3105.
104. Breitkreutz I, Raab MS, Vallet S, et al. Lenalidomide inhibits osteoclastogenesis, survival factors and bone-remodeling markers in multiple myeloma. Leukemia 2008; 22:1925-1932.
105. Berenson JR, Yellin O, Crowley J, et al. Prognostic factors and jaw and renal complications among multiple myeloma patients treated with zoledronic acid. Am J Hematol 2011; 86:25-30.
106. Facchini G, Caraglia M, Morabito A, et al. Metronomic administration of zoledronic acid and taxotere combination in castration resistant prostate cancer patients. Cancer Biol Ther 2010; 10:543-548.
107. Horie N, Murata H, Kimura S, et al. Combined effects of a third-generation bisphosphonate, zoledronic acid with other anticancer agents against murine osteosarcoma. Br J Cancer 2007; 96:255-261. (Pubitemid 46160630)
108. Meyers PA, Healey JH, Chou AJ, et al. Addition of pamidronate to chemotherapy for the treatment of osteosarcoma. Cancer 2011; 117:1736-1744.
109. Balke M, Campanacci L, Gebert C, et al. Bisphosphonate treatment of aggressive primary, recurrent and metastatic giant cell tumour of bone. BMC Cancer 2010; 10:462.
110. Novartis. A study to evaluate the safety and efficacy of zoledronic acid in the prevention or delaying of bone metastasis in patients with stage IIIA and IIIB nonsmall cell lung cancer. ClinicalTrials.gov Identifier, NCT00172042. http://clinicaltrials.gov/ct2/showNCT00172042?term=NCT00172042%26rank=1 [Accessed 14 December 2009].